Nanosuspensions of alendronate with gallium or gadolinium attenuate neointimal hyperplasia in rats

被引:37
作者
Epstein, Hila [1 ]
Berger, Vardit [1 ]
Levi, Idit [1 ]
Eisenberg, Galit [1 ]
Koroukhov, Nickolay [1 ]
Gao, Jianchuan [1 ]
Golomb, Gershon [1 ]
机构
[1] Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmaceut, Fac Med, IL-91120 Jerusalem, Israel
关键词
nanosuspension; liposomes; gallium; gadolinium; bisphosphonates; alendronate; restenosis; monocytes/macrophages; immunomodulation; antiinflammatory;
D O I
10.1016/j.jconrel.2006.10.030
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Monocytes/macrophages play a pivotal role in the formation of neointinal hyperplasia following vascular injury. Transient depletion of circulating monocytes by particulate delivery systems containing bisphosphonates, such as alendronate, results in restenosis inhibition. We hypothesized that a self-suspendable natroparticulate dosage form, with a minimum amount of expients, could be formulated by complexing the negatively charged alendronate with gallium or gadolinium. We further hypothesized that a synergistic biological effect could be obtained by nanosuspensions of alendronate with these counter ions. Nanosuspensions (150-250 nm) of alendronate-gallium and alendronate-gadolinium were successfully formulated with no additives except for the active agents and HCl for pH adjustment. Both nanosuspensions exhibited macrophage cell line growth inhibition in a dose-response relationship in comparison to the various agents in solution and in liposomes. A synergistic effect of the nanosuspensions was observed in the inhibition of raw264 macrophages, and in reducing IL-1 beta and TNF-alpha secretion in cell culture. Single IV administration at the time of injury, of alendronate-gallium or alendronate-gadolinium nanosuspensions resulted in inhibition of neointimal hyperplasia and stenosis in the rat model of vascular injury. The results correlated with the significant reduction of circulating monocytes. The nanosuspensions possess the advantages of no additives for minimal provocation of side effects, and the potential of immunomodulating inflammatory disorders. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:322 / 332
页数:11
相关论文
共 52 条
[1]   THE ACUTE-PHASE RESPONSE AFTER BISPHOSPHONATE ADMINISTRATION [J].
ADAMI, S ;
BHALLA, AK ;
DORIZZI, R ;
MONTESANTI, F ;
ROSINI, S ;
SALVAGNO, G ;
LOCASCIO, V .
CALCIFIED TISSUE INTERNATIONAL, 1987, 41 (06) :326-331
[2]  
Adding LC, 2001, CARDIOVASC DRUG REV, V19, P41
[3]  
Allemann E, 1997, J BIOMED MATER RES, V37, P229, DOI 10.1002/(SICI)1097-4636(199711)37:2<229::AID-JBM12>3.0.CO
[4]  
2-9
[5]   Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries [J].
Banai, S ;
Chorny, M ;
Gertz, SD ;
Fishbein, I ;
Gao, JC ;
Perez, L ;
Lazarovichi, G ;
Gazit, A ;
Levitzki, A ;
Golomb, G .
BIOMATERIALS, 2005, 26 (04) :451-461
[6]  
BARTLETT GR, 1959, J BIOL CHEM, V234, P466
[7]  
Bernstein LR, 1998, PHARMACOL REV, V50, P665
[8]  
Bushrab FN., 2003, J New Drugs, V5, P20
[9]   Bisphosphonates and tetracycline:: Experimental models for their evaluation in calcium-related disorders [J].
Cohen, H ;
Solomon, V ;
Alferiev, IS ;
Breuer, E ;
Ornoy, A ;
Patlas, N ;
Eidelman, N ;
Hägele, G ;
Golomb, G .
PHARMACEUTICAL RESEARCH, 1998, 15 (04) :606-613
[10]   Alendronate-loaded nanoparticles deplete monocytes and attenuate restenosis [J].
Cohen-Sela, Einat ;
Rosenzweig, Ohad ;
Gao, Jianchuan ;
Epstein, Hila ;
Gati, Irith ;
Reich, Reuven ;
Danenberg, Haim D. ;
Golomb, Gershon .
JOURNAL OF CONTROLLED RELEASE, 2006, 113 (01) :23-30